Ketamine for alcoholics trial goes to next stage
BBC - 13 December 2022.
The clinical trial led by the University of Exeter and Awakn Life Sciences, with funding of 2.4 million pounds, will take place in seven NHS centers across the UK. The research will go ahead after a previous study revealed that participants who took ketamine combined with psychotherapy (KARE) remained completely sober, representing 86% abstinence at the six-month follow-up. The Ketamine for Alcohol Relapse Reduction (KARE) trial will now move on to the next stage of the drug's development, with the aim of introducing it on the NHS.
